Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bixolecumab
- Development stage
- Phase 1
- Lead developer
- Akeso
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Bixolecumab is a humanized monoclonal antibody designed to target proprotein convertase subtilisin/kexin type 9 (PCSK9). Developed by Kangrong Oriental (Guangdong) Pharmaceutical, it is primarily indicated for the treatment of primary hypercholesterolemia and mixed dyslipidemia. The drug functions by binding to circulating PCSK9, preventing it from interacting with low-density lipoprotein receptors (LDLR) on the surface of hepatocytes. By inhibiting PCSK9-mediated degradation of LDLR, bixolecumab increases the density of these receptors, thereby enhancing the clearance of LDL cholesterol from the bloodstream. It is currently undergoing Phase 3 clinical evaluation in China.
- Brand names
- Yixin Ning
02
Targets
PCSK9 (Proprotein convertase subtilisin/kexin type 9)
Beyond the preview
Go deeper on bixolecumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bixolecumab.